December 11th, 2017
jobs
homes

Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Amphastar Pharmaceuticals, Inc. - Common Stock (NQ:AMPH)

25.28 -0.07 (-0.28%)
Delayed Quote Updated: 11:34 AM EDT, Oct 2, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Amphastar Pharmaceuticals, Inc. - Common Stock

< Previous 1 2
...
6 7 8 9 10 11 12 13 Next >
News headline image
Top 2 Small Cap Healthcare Stocks to Buy Before Rate Cuts
These 2 small cap healthcare stocks could boom on a new sector breakout, Wall Street analysts see up to double-digit upside in each 
Via MarketBeat
Topics ETFs Economy
News headline image
Why the growth investor may take a look at NASDAQ:AMPH. ↗
AMPHASTAR PHARMACEUTICALS IN (NASDAQ:AMPH) may be suited for growth investing, we'll explore why in this article. 
Via Chartmill
News headline image
Amphastar Announces Additional $50 Million Increase to its Share Buyback Program
Via ACCESSWIRE
News headline image
Amphastar Pharmaceuticals to Present at the Jefferies Global Healthcare Conference
Via ACCESSWIRE
News headline image
Amphastar Receives FDA Approval for Albuterol Sulfate Inhalation Aerosol
Via ACCESSWIRE
News headline image
Exploring NASDAQ:AMPH's growth characteristics. ↗
AMPHASTAR PHARMACEUTICALS IN (NASDAQ:AMPH) showing high EPS and FCF growth while beating expectations 
Via Chartmill
News headline image
Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended March 31, 2024
Via ACCESSWIRE
News headline image
NASDAQ:AMPH, an undervalued stock with good fundamentals. ↗
AMPHASTAR PHARMACEUTICALS IN (NASDAQ:AMPH): good value for what you're paying. 
Via Chartmill
News headline image
Patent Peril: 3 Stocks at Risk From the FTC’s Drug Crusade ↗
The FTC is putting these three drug stocks at risk by trying to strip their therapies of protection from generics. 
Via InvestorPlace
Topics Intellectual Property
News headline image
Amphastar Pharmaceuticals to Present at the Bank of America Securities Health Care Conference
Via ACCESSWIRE
News headline image
AMPH Stock Earnings: Amphastar Pharma Beats EPS, Misses Revenue for Q1 2024 ↗
AMPH stock results show that Amphastar Pharma beat analyst estimates for earnings per share but missed on revenue for the first quarter of 2024. 
Via InvestorPlace
News headline image
Federal Trade Commission Targets 'Junk Patent Listings' For Diabetes, Weight Loss, Asthma Drugs From Companies Like Novo Nordisk, AstraZeneca ↗
The FTC intensifies efforts against pharmaceutical patent listings, disputing junk patents for diabetes, weight loss, asthma, and COPD medications. This initiative combats tactics hindering generic... 
Via Benzinga
Topics Intellectual Property
News headline image
Amphastar Pharmaceuticals to Release First Quarter Earnings and Hold Conference Call on May 8, 2024
Via ACCESSWIRE
News headline image
Amphastar Pharmaceuticals Reports Financial Results for the Three Months and Full-Year Ended December 31, 2023
Via ACCESSWIRE
News headline image
Delving into NASDAQ:AMPH's Growth Prospects. ↗
Should you consider AMPHASTAR PHARMACEUTICALS IN (NASDAQ:AMPH) for growth investing? 
Via Chartmill
News headline image
Earnings Outlook For Amphastar Pharma ↗
 
Via Benzinga
News headline image
Amphastar Pharmaceuticals Interested In Potential Acquisitions In Endocrinology-Focused Companies ↗
Amphastar Pharmaceuticals discusses the future of Baqsimi at the Needham Healthcare Conference, highlighting its potential amid a growing market for glucagon products. With promising sales projections... 
Via Benzinga
News headline image
Amphastar Pharmaceuticals to Present at the 23rd Annual Needham Virtual Healthcare Conference
Via ACCESSWIRE
News headline image
Amphastar Pharmaceuticals to Present at the Barclays 26th Annual Global Healthcare Conference
Via ACCESSWIRE
News headline image
Amphastar Pharmaceuticals to Release Fourth Quarter Earnings and Hold Conference Call on February 28, 2024
Via ACCESSWIRE
News headline image
Is NASDAQ:AMPH a Fit for Growth Investing Strategies? ↗
Is AMPHASTAR PHARMACEUTICALS IN (NASDAQ:AMPH) suited for growth investing? 
Via Chartmill
News headline image
Is NASDAQ:AMPH a Fit for Growth Investing Strategies? ↗
Why AMPHASTAR PHARMACEUTICALS IN (NASDAQ:AMPH) qualifies as a high growth stock. 
Via Chartmill
News headline image
Unlocking the Growth Potential of NASDAQ:AMPH. ↗
Exploring AMPHASTAR PHARMACEUTICALS IN (NASDAQ:AMPH)'s growth characteristics. 
Via Chartmill
News headline image
NASDAQ:AMPH is not too expensive for the growth it is showing. ↗
Looking for growth without the hefty price tag? Consider NASDAQ:AMPH. 
Via Chartmill
News headline image
CRISPR Therapeutics Stock Shows Rising Relative Strength, Hits 90+ ↗
CRISPR Therapeutics shows improving price performance, earning an upgrade to its IBD Relative Strength Rating. 
Via Investor's Business Daily
News headline image
3 Once-in-a-Lifetime Biotech Stocks With Unprecedented Surge Potential ↗
As the new business cycle gets started, here are some biotech stocks with potential that investors should pay attention to. 
Via InvestorPlace
News headline image
Axsome Therapeutics Stock Showing Leadership, Earns 91 RS Rating ↗
Axsome Therapeutics shows improving price performance, earning an upgrade to its IBD Relative Strength Rating. 
Via Investor's Business Daily
News headline image
Despite its impressive fundamentals, NASDAQ:AMPH remains undervalued. ↗
For those who appreciate value investing, AMPHASTAR PHARMACEUTICALS IN (NASDAQ:AMPH) is a compelling option with its solid fundamentals. 
Via Chartmill
News headline image
What Vitamins Did For Healthy Living, Stemtech Corporation (OTCQB: STEK) Says It Is Doing For Anti-Aging With Stem Cell Nutrition ↗
Vitamins may not be a miracle cure, but combined with exercise and a healthy diet, they have the potential to greatly improve health and wellness. It’s no wonder vitamin supplements are a multi-billion... 
Via Benzinga
News headline image
Jim Cramer Says Hold Onto This Biotech Stock: 'I Don't Understand Why It's So Inexpensive' ↗
On CNBC’s "Mad Money Lightning Round," Jim Cramer said he would back Moderna, Inc. (NASDAQ: MRNA) here. 
Via Benzinga
< Previous 1 2
...
6 7 8 9 10 11 12 13 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

More ways to get to us

Lethbridge Herald Facebook Facebook
Lethbridge Herald Twitter Twitter
Lethbridge Herald YouTube YouTube

About Us

Contact the Lethbridge Herald

504 - 7th Street South
Lethbridge, AB T1J 3Z7

[P] (403) 328-4411
[F] (403)328-4536

Print Advertising: (403) 328-4410
National Advertising: (403) 380-7585
Online Advertising: (403) 380-7585
Classifieds: (403) 328-4433

© 1996-2017 The Lethbridge Herald, A Division of Continental Newspapers Canada Ltd.